Did you know?

ChinaBio® Group is a consulting and advisory firm helping life science companies and investors achieve success in China. ChinaBio works with U.S., European and APAC companies and investors seeking partnerships, acquisitions, novel technologies and funding in China.  

Learn more >>

Free Newsletter

Have the latest stories on China's life science industry delivered to your inbox daily or weekly - free!

See preview >>

  Email address:
   

Gritgen’s Gene Therapy for Hemophilia 100% Effective in IIT Trial

publication date: Nov 16, 2023

Suzhou Gritgen Therapeutics reported its novel gene therapy for Hemophilia A (HA) posted 100% effective results in the first 12 weeks following treatment. The Investigator Initiated Trial enrolled 12 patients with severe HA whose endogenous factor VIII (FVIII) activity was lower than 1%. All patients were treated with a single dose of GS1191 by mid-May. Currently, all patients enrolled in the high dose group have normal FVIII activities with no bleeding episodes observed. Gritgen has begun its own China Phase I trial of GS1191 in patients with severe HA. More details....

Share this with colleagues:  


This article is available for purchase - please click here for details.

Sorry this page is available to subscribers only.
If you're not a subscriber why not subscribe today?

If you are already a subscriber, please login.

If you believe you should have received this message in error, please contact us.


 

To gain access to the members only content click here to subscribe.

You will be given immediate access to premium content on the site.

ChinaBio® News

Greg Scott BIO-Europe Interview
Greg Scott Interviewed at BIO-Europe Spring

How to bring your China assets to China in 8 minutes

Greg Scott Mendelspod Interview
"Mr. Bio in China."
Mendelspod Interview

Multinational pharma held to a higher standard in China

Partner Event
November 2-3, 2023 | Shanghai
November 7-8, 2023 | Digital